

## HERCEPTIN AUTHORIZATION REQUEST

Dear

This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. Please respond below and fax this form to Peachstate toll-free at 866-374-1579. If you have questions regarding the prior authorization, please contact Peachstate toll-free at 800-514-0083 option # 2.

Patient Name:

Physician Name:

Patient ID#:

Physician Phone

Patient Date of Birth:

Physician Fax:

1. Which drug is being prescribed?  Herceptin Dose: \_\_\_\_\_ Frequency \_\_\_\_\_  Other \_\_\_\_\_
2. What is the diagnosis?  Breast Cancer (Adjuvant treatment)  Metastatic Breast Cancer  
 Metastatic Gastric Cancer/gastroesophageal junction adenocarcinoma  
 Other \_\_\_\_\_
3. What is the medical specialty of the prescribing physician?  oncologist  other
4. Does the member have HER2 positive disease?  Yes  No
5. Will left ventricular function be monitored prior to initiation of therapy and every 3-4 months thereafter?
6. For Breast Cancer (adjuvant), is the breast cancer node positive or node negative?  Positive  Negative
7. For Breast Cancer (adjuvant) and node negative, is the breast cancer ER/PR positive or ER/PR negative?  
 Positive  Negative
8. For Breast Cancer (adjuvant) and ER/PR positive, is the breast cancer associated with any of the following high risk features?  
 Tumor size > 2 cm  
 Age < 35 years  
 Histologic and/or nuclear grade 2 or 3
9. For Breast Cancer (adjuvant) select the treatment regimen:  
 Consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel  
 Consisting of docetaxel and carboplatin  
 As a single agent following multi-modality anthracycline based therapy  
 Other \_\_\_\_\_
10. For Metastatic Breast Cancer select the treatment regimen in conjunction with Herceptin:  
 Combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer  
 As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease
11. For Metastatic Gastric or Gastroesophageal junction adenocarcinoma include a combination with cisplatin and capecitabine or 5-fluorouracil, who have not received prior treatment for metastatic disease?  
 Yes  No
12. Please attach chemotherapy treatment regimen.

**HERCEPTIN AUTHORIZATION REQUEST**

13. Is the patient pregnant?  Yes  No

14. Does the patient have a diagnosis or history of one of the following:

- Cardiomyopathy  Decrease in left ventricular ejection fraction  
 Prior infusion reaction to Herceptin  Chemotherapy-induced neutropenia  None

**SECTION A: Recertification**

1. Has there been any symptom issue?  Yes  No

2. What symptom(s) or events are being monitored? \_\_\_\_\_

3. Has the member experienced a clinically significant decrease in left ventricular function?

4. Had Herceptin been previously withheld?  Yes  No

5. For how many weeks has patient been on therapy? \_\_\_\_\_ weeks

6. Has the patient been compliant with therapy and tolerating well?  Yes  No

7. Has disease progressed or no change?  Yes  No

8. Will the dose:  Continue the same as starting dose  decreased \_\_\_\_\_ %  increased \_\_\_\_\_ %

*Information given on this form is accurate as of this date*

---

**Prescriber or Authorized Signature**

**Date**

**\*\*\*NOTE:: We can NOT make a decision without a copy of lab results - Thank You**